Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Athira Pharma, Inc. (ATHA)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 30,820,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Athira Pharma is a late clinical-stage biopharmaceutical company. Co.'s primary candidate, fosgonimeton (ATH-1017), is a blood brain barrier-penetrating, small molecule hepatocyte growth factor (HGF)/MET positive modulator. The primary target indication is Alzheimer's disease (AD). Co.'s product candidate for its neuropsychiatric program is ATH-1020, which is a small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and to distribute to the central nervous system. Co. has several preclinical candidates for non-AD indications, including ATH-1019, which is being developed to address peripheral indications such as peripheral neuropathy.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 605,686
Total Buy Value $0 $0 $0 $1,462,896
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 3
Total Shares Sold 0 55,834 69,713 82,977
Total Sell Value $0 $31,374 $39,229 $77,827
Total People Sold 0 5 7 7
Total Sell Transactions 0 5 10 15
End Date 2025-03-30 2024-12-27 2024-06-28 2023-06-29

   
Records found: 123
  Page 1 of 5  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Church Kevin CHIEF SCIENTIFIC OFFICER   •       –      –    2025-01-02 4 S $0.56 $4,782 D/D (8,510) 130,761     -
   Litton Mark James President and CEO   •       •      –    2025-01-02 4 S $0.56 $14,108 D/D (25,107) 242,591     -
   Worthington Mark General Counsel and CCO   •       –      –    2025-01-02 4 S $0.56 $4,782 D/D (8,510) 83,735     -
   San Martin Javier CHIEF MEDICAL OFFICER   •       –      –    2025-01-02 4 S $0.56 $6,083 D/D (10,826) 35,841     -
   Renninger Robert VP of Finance   •       –      –    2025-01-02 4 S $0.56 $1,619 D/D (2,881) 89,724     -
   Church Kevin CHIEF SCIENTIFIC OFFICER   •       –      –    2024-12-31 4 OE $0.00 $0 D/D 36,667 139,271     -
   Litton Mark James President and CEO   •       •      –    2024-12-31 4 OE $0.00 $0 D/D 108,333 267,698     -
   Worthington Mark General Counsel and CCO   •       –      –    2024-12-31 4 OE $0.00 $0 D/D 36,667 92,245     -
   San Martin Javier CHIEF MEDICAL OFFICER   •       –      –    2024-12-31 4 OE $0.00 $0 D/D 46,667 46,667     -
   Renninger Robert VP of Finance   •       –      –    2024-12-31 4 OE $0.00 $0 D/D 12,359 92,605     -
   Church Kevin CHIEF SCIENTIFIC OFFICER   •       –      –    2024-11-18 4 A $0.55 $5,456 D/D 9,920 102,604     -
   Worthington Mark General Counsel and CCO   •       –      –    2024-11-18 4 A $0.55 $2,008 D/D 3,651 55,578     -
   Renninger Robert VP of Finance   •       –      –    2024-11-18 4 A $0.55 $2,008 D/D 3,651 80,246     -
   Renninger Robert VP of Finance   •       –      –    2024-10-01 3 IO $0.00 $0 D/D 0 76,595     -
   Litton Mark James President and CEO   •       •      –    2024-09-05 4 S $0.57 $2,848 D/D (5,032) 159,365     -
   Lenington Rachel COO and CDO   •       –      –    2024-09-05 4 S $0.57 $1,429 D/D (2,525) 20,870     -
   Church Kevin CHIEF SCIENTIFIC OFFICER   •       –      –    2024-09-05 4 S $0.57 $1,429 D/D (2,525) 92,684     -
   Worthington Mark GENERAL COUNSEL   •       –      –    2024-09-05 4 S $0.57 $1,429 D/D (2,525) 51,927     -
   Gengos Andrew CFO and Chief Business Officer   •       –      –    2024-09-05 4 S $0.57 $720 D/D (1,272) 97,532     -
   Litton Mark James President and CEO   •       •      –    2024-09-03 4 A $0.00 $0 D/D 20,000 164,397     -
   Lenington Rachel COO and CDO   •       –      –    2024-09-03 4 A $0.00 $0 D/D 10,000 23,395     -
   Church Kevin CHIEF SCIENTIFIC OFFICER   •       –      –    2024-09-03 4 A $0.00 $0 D/D 10,000 95,209     -
   Worthington Mark GENERAL COUNSEL   •       –      –    2024-09-03 4 A $0.00 $0 D/D 10,000 54,452     -
   Gengos Andrew CFO and Chief Business Officer   •       –      –    2024-09-03 4 A $0.00 $0 D/D 5,000 98,804     -
   Church Kevin CHIEF SCIENTIFIC OFFICER   •       –      –    2024-05-20 4 A $1.34 $6,637 D/D 4,953 85,209     -
  123 Records found
  1  2  3  4  5   
  Page 1 of 5
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us